Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of 1,25-Dihydroxy Vitamin D Assay

12 Dec 2014 07:00

RNS Number : 5807Z
Immunodiagnostic Systems Hldgs PLC
12 December 2014
 



12 December 2014

 

 

Immunodiagnostic Systems Holdings plc.

 

Launch of Fully Automated 1,25-Dihydroxy Vitamin D Assay

 

 

Immunodiagnostic Systems Holdings plc (IDS), a leading solution provider to the clinical laboratory diagnostic market, today announced it has received European CE Mark declaration for the IDS-iSYS 1,25 VitDXp assay - a fully automated assay for use with the IDS-iSYS Multi-Discipline Automated System.

 

The IDS-iSYS 1,25 VitDXp assay assesses 1,25-Dihydroxy Vitamin D status and deficiencies associated with renal disease and disorders of calcium metabolism. Market value of 1,25-Dihyroxy Vitamin D testing is estimated to be circa £15 million per annum in Europe.

 

Patrik Dahlen, CEO of IDS, said: "Continuing IDS's heritage and expertise in endocrinology and Vitamin D testing, the IDS-iSYS 1,25 VitDXp uses a proven and trusted technology to fully automate purification and quantification of 1,25-Dihydroxy Vitamin D. The excellent assay stability, walk away convenience and ease-of-use provides laboratories significant workflow and productivity advantages."

 

Available now, IDS offers laboratories evaluating calcium metabolism and Vitamin D deficiencies a comprehensive, fully automated solution.

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 5190660

Patrik Dahlen, CEO

Chris Yates, CFO

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel / Jock Maxwell Macdonald

FTI Consulting

Tel : +44 (0)203 727 1000

Ben Atwell / Simon Conway / Mo Noonan

 

 

About Immunodiagnostic Systems Holdings PLC

The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTBBJTMBTBTJI
Date   Source Headline
10th Sep 20147:00 amRNSAcquisition of Dia.Metra S.r.l.
21st Aug 20147:00 amRNSChinese FDA clearance for the IDS-iSYS instrument
4th Aug 20145:59 pmRNSAGM Results
4th Aug 20147:00 amRNSAGM Statement
30th Jul 201410:25 amRNSAdditional Listing
14th Jul 201411:36 amRNS2014 Annual Report & Accounts and Notice of AGM
24th Jun 20147:00 amRNSFinal Results
12th May 201410:51 amRNSHolding(s) in Company
15th Apr 20147:00 amRNSTrading Statement
13th Mar 20144:40 pmRNSSecond Price Monitoring Extn
13th Mar 20144:35 pmRNSPrice Monitoring Extension
7th Mar 20147:00 amRNSDirectorate Change
15th Jan 20144:28 pmRNSHolding(s) in Company
9th Jan 20147:00 amRNSFDA clearance of Direct Renin assay on IDS-iSYS
8th Jan 201412:47 pmRNSAdditional Listing
19th Dec 20134:36 pmRNSAdditional Listing
12th Dec 20136:20 pmRNSHolding(s) in Company
12th Dec 20136:19 pmRNSHolding(s) in Company
27th Nov 20137:00 amRNSHalf Yearly Report
10th Oct 20137:00 amRNSTrading Statement
8th Oct 20134:29 pmRNSHolding(s) in Company
8th Oct 20134:26 pmRNSHolding(s) in Company
27th Sep 201312:40 pmRNSHolding(s) in Company
24th Sep 20131:15 pmRNSAdditional Listing
4th Sep 20137:00 amRNSHolding(s) in Company
28th Aug 201312:46 pmRNSAdditional Listing
31st Jul 201312:20 pmRNSAdditional Listing
29th Jul 20133:24 pmRNSHolding(s) in Company
26th Jul 20133:08 pmRNSResult of AGM
26th Jul 201312:00 pmRNSAGM Statement
2nd Jul 20139:41 amRNSDirector/PDMR Shareholding
28th Jun 20139:46 amRNSAdditional Listing
28th Jun 20139:00 amRNSAnnual Report and AGM
26th Jun 20137:00 amRNSAdditional Listing
24th Jun 20137:00 amRNSFDA clearance of 1,25-Dihydroxy Vitamin D assay
21st Jun 20137:00 amRNSImmunodiagnostic Systems streamlines Board
17th Jun 20137:00 amRNSFinal Results
10th May 20134:29 pmRNSHolding(s) in Company
9th May 20133:22 pmRNSAdditional Listing
2nd May 20137:41 amRNSEntry into Chinese Diagnostics Market
25th Apr 20134:17 pmRNSTrading Update - Replacement
23rd Apr 20139:45 amRNSHolding(s) in Company
16th Apr 20135:03 pmRNSHolding(s) in Company
16th Apr 201311:42 amRNSHolding(s) in Company
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Statement
5th Apr 201310:22 amRNSDirector/PDMR Shareholding
4th Apr 20134:43 pmRNSHolding(s) in Company
11th Feb 20137:00 amRNSCollaboration with Diagnostica Stago
14th Dec 20122:28 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.